We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$213M
Cap. Flow
-$89.6M
Cap. Flow %
-7.9%
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
32
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$43.3M
2
TERN
Terns Pharmaceuticals
TERN
+$30M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$23.4M
4
TXG icon
10x Genomics
TXG
+$18.8M
5
ELVN icon
Enliven Therapeutics
ELVN
+$16.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$44.7M
2
UTHR icon
United Therapeutics
UTHR
+$31.3M
3
HCA icon
HCA Healthcare
HCA
+$17.2M
4
BIIB icon
Biogen
BIIB
+$15.7M
5
WGS icon
GeneDx Holdings
WGS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Consumer Staples 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
101
HCA Healthcare
HCA
$86.8B
– –
-51,441
Closed -$17.2M
KALV
102
DELISTED
KalVista Pharmaceuticals
KALV
– –
-386,000
Closed -$4.58M
LQDA icon
103
Liquidia Corp
LQDA
$7.86B
– –
-10,000
Closed -$148K
MNKD icon
104
MannKind Corp
MNKD
$1.22B
– –
-1,558,537
Closed -$7.06M
DFTX
105
Definium Therapeutics
DFTX
$5.62B
– –
-750,237
Closed -$7.05M
NKTX icon
106
Nkarta
NKTX
$162M
– –
-300,000
Closed -$3.24M
PTGX icon
107
Protagonist Therapeutics
PTGX
$8.73B
– –
-34,500
Closed -$998K
RGLS
108
DELISTED
Regulus Therapeutics
RGLS
– –
-1,562,500
Closed -$4.5M
TMDX icon
109
Transmedics
TMDX
$2.79B
– –
-16,700
Closed -$1.23M
TNYA icon
110
Tenaya Therapeutics
TNYA
$161M
– –
-122,222
Closed -$639K
TSHA icon
111
Taysha Gene Therapies
TSHA
$1.78B
– –
-925,000
Closed -$2.65M
URGN icon
112
UroGen Pharma
URGN
$1.94B
– –
-10,000
Closed -$150K
VKTX icon
113
Viking Therapeutics
VKTX
$3.84B
– –
-67,121
Closed -$5.5M
XBI icon
114
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.92B
– –
-2,200,000
Closed -$209M
SILK
115
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-10,000
Closed -$183K
INBX
116
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-267,871
Closed -$9.36M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Soleus Capital Management held 116 positions worth $1.13B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Soleus Capital Management withdrew a net $89.6M in Q2 2024, closing 24 positions and reducing 25 holdings. Its most notable exit was HCA Healthcare, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Terns Pharmaceuticals worth $33.7M.

  • Soleus Capital Management's largest Q2 2024 buy was Terns Pharmaceuticals: 4,947,738 shares worth $33.7M.
  • Soleus Capital Management added most to Iovance Biotherapeutics in Q2 2024, an estimated $43.3M increase.
  • Soleus Capital Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $44.7M.
  • Soleus Capital Management fully exited HCA Healthcare in Q2 2024, selling an estimated $17.2M.
  • Soleus Capital Management's ten largest holdings make up 37% of its $1.13B portfolio in Q2 2024.
  • Soleus Capital Management opened 25 new positions and closed 24 in Q2 2024.
  • Soleus Capital Management's portfolio value fell 16% quarter-over-quarter to $1.13B.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.